Want to see SE:IMMNOV full AI Analyst Report?
IMMNOV Stock Chart & Stats
kr0.16
>-kr0.01(-5.58%)
At close: 4:00 PM EDT
kr0.16
>-kr0.01(-5.58%)
Day’s Range― - ―
52-Week Rangekr0.06 - kr0.36
Previous CloseN/A
Volume5.99M
Average Volume (3M)6.58M
Market Cap
kr59.60M
Enterprise Valuekr99.54M
Total Cash (Recent Filing)kr34.90M
Total Debt (Recent Filing)kr3.27M
Price to Earnings (P/E)―
Beta1.03
Next Earnings
Nov 05, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.17
Shares Outstanding672,666,900
10 Day Avg. Volume8,788,620
30 Day Avg. Volume6,580,185
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.21
Price to Sales (P/S)114.10
P/FCF Ratio-1.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.1
Revenue Forecast (FY)kr3.00M
Bulls Say, Bears Say
Bulls Say
Clinical ValidationStrong sensitivity and specificity in a high-risk subgroup support the test’s clinical credibility and Medicare submission. If these results translate into broader clinical utility, they can strengthen adoption, reimbursement discussions, and Immunovia’s position in early pancreatic cancer detection.
Commercial TractionGrowing use across high-profile cancer centers and a larger engaged pipeline indicate that PancreaSure is gaining institutional awareness beyond initial launch activity. Continued conversion of these prospects into recurring orders could establish a durable commercial base and improve operating leverage.
Low LeverageLow leverage limits the pressure from mandatory debt service and preserves greater balance-sheet flexibility than a heavily indebted structure would provide. This gives management more room to pursue commercialization and partnerships, although it does not eliminate the need to fund ongoing operating losses.
Bears Say
Minimal Scale And Heavy LossesThe company remains far from a self-sustaining operating model: revenue is small relative to expenses, gross profit is negative, and net losses remain substantial. Until commercial growth materially improves the cost-revenue relationship, profitability and the path to breakeven remain uncertain.
Cash Burn And Financing NeedPersistent negative operating and free cash flow means Immunovia must continue funding its business externally while scaling sales and clinical programs. The stated runway into Q4 2026 creates a near-term need for financing or partnerships, which could constrain strategy and shareholder returns.
Reimbursement UncertaintyUncertain reimbursement timing and realized payment levels make future revenue conversion difficult to forecast, even where clinical demand exists. Restricted Medicare coverage for symptomatic high-risk patients could also limit the reimbursed population, slowing adoption and delaying progress toward sustainable economics.
Immunovia AB News
IMMNOV FAQ
What was Immunovia AB’s price range in the past 12 months?
Immunovia AB lowest stock price was kr0.06 and its highest was kr0.35 in the past 12 months.
What is Immunovia AB’s market cap?
Immunovia AB’s market cap is kr59.60M.
When is Immunovia AB’s upcoming earnings report date?
Immunovia AB’s upcoming earnings report date is Nov 05, 2026 which is in 17 days.
How were Immunovia AB’s earnings last quarter?
Immunovia AB released its earnings results on Aug 06, 2026. The company reported -kr0.03 earnings per share for the quarter, beating the consensus estimate of -kr0.04 by kr0.01.
Is Immunovia AB overvalued?
According to Wall Street analysts Immunovia AB’s price is currently Overvalued.
Does Immunovia AB pay dividends?
Immunovia AB does not currently pay dividends.
What is Immunovia AB’s EPS estimate?
Immunovia AB’s EPS estimate is -0.02.
How many shares outstanding does Immunovia AB have?
Immunovia AB has 672,666,900 shares outstanding.
What happened to Immunovia AB’s price movement after its last earnings report?
Immunovia AB reported an EPS of -kr0.03 in its last earnings report, beating expectations of -kr0.04. Following the earnings report the stock price went down -3.846%.
Which hedge fund is a major shareholder of Immunovia AB?
Currently, no hedge funds are holding shares in SE:IMMNOV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Immunovia AB
Immunovia AB (publ), a diagnostic company, develops blood diagnostic for detecting pancreatic cancer in Sweden. It also focuses on the development and commercialization of blood-based testing to detect proteins and antibodies that indicate pancreatic cancer in an individual. Immunovia AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
IMMNOV Company Deck
IMMNOV Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed meaningful commercial, scientific and reimbursement progress: a successful product launch, strong clinical publications and podium presence, an awarded Medicare pricing of USD 897, state approvals in 48 states, targeted hiring of account managers, and a completed rights issue that improved cash position. However, near-term revenue remains limited, full payer coverage is not yet granted, cash runway extends only to Q3 2026 without additional capital, and realized per-test pricing and collections are still uncertain. The company emphasized disciplined spending, planned clinical utility data collection (including a 400-patient registry) and a mid-2026 Medicare submission with rolling data updates to mitigate coverage risk.View all SE:IMMNOV earnings summariesTechnical Analysis
Biosergen AB
―
Q-linea AB
―
Acarix AB
―
Biovica International AB Class B
―
Devyser Diagnostics AB
―